In a phase II study (NCT03264066) of patients with HNSCC, the combination of cobimetinib (an MEK inhibitor) and atezolizumab (an anti-PD-L1 monoclonal antibody) resulted in a 20% response rate [4]. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.